Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study- few concerns

BMC Pulm Med. 2024 Mar 15;24(1):132. doi: 10.1186/s12890-024-02951-9.

Abstract

This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.

Publication types

  • Letter
  • Comment

MeSH terms

  • Albuterol
  • Bronchodilator Agents*
  • Fluticasone-Salmeterol Drug Combination / therapeutic use
  • Humans
  • Non-Smokers
  • Obesity, Morbid*

Substances

  • Bronchodilator Agents
  • Albuterol
  • Fluticasone-Salmeterol Drug Combination